June 7th 2024
Now more than two years into launching his alternative and transparent drug payment model, the longtime entrepreneur, in an interview with Pharm Exec, discusses the prescription drug cost landscape and shares his recipe for true disruption to the pharma pricing machine.
Drug Price Controls: “Red Meat for the Left” or Russian Roulette?
September 18th 2015Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.
Partnering in a Volume to Value Transformational Environment
March 12th 2015In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.